Drug profile · INN
olopatadine hydrochloride
OLOPATADINE HYDROCHLORIDE
olopatadine hydrochloride (OLOPATADINE HYDROCHLORIDE) is a histamine h1 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — olopatadine hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
olopatadine hydrochloride (OLOPATADINE HYDROCHLORIDE) is a histamine h1 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12404275
Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
granted -
US 12304898
Quinolyl-containing compound and pharmaceutical composition, and use thereof
granted -
US 12129258
Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
granted -
US 12059443
Method for treating cancer using dengue virus serotype 1 (DENV-1)
granted -
US 11896623
Visco-supplement compositions, and methods of use thereof
granted -
US 11781247
Variable epitope library compositions and methods of therapeutic and prophylactic use
granted -
US 11491190
Visco-supplement compositions, and methods of use thereof
granted -
US 11389497
Pharmaceutical composition for treating cancer
granted -
US 10945964
Microencapsulated chitosan, methods of making and methods for the use thereof
granted -
US 10765705
Visco-supplement compositions, and methods of use thereof
granted -
US 10537611
Methods of treating lung cancer
granted -
US 10517902
Expandable amnion membrane for treating non-healing wounds
granted -
US 10383927
Variable epitope library compositions and methods of therapeutic and prophylactic use
granted -
US 10195612
Small particle compositions and associated methods
granted -
US 10130676
Therapeutic peptides for cerebrovascular diseases
granted -
US 10023627
Vascular endothelial growth factor fusion protein
granted -
US 10016484
Methods of treating lung cancer
granted -
US 9192683
Methods of treating disease with FGFR1 fusion proteins
granted -
US 9173957
FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
granted -
US 8871907
Glycosylated immunoglobulin and immunoadhesin comprising the same
granted
Frequently asked questions
What is olopatadine hydrochloride?
olopatadine hydrochloride (OLOPATADINE HYDROCHLORIDE) is a histamine h1 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for olopatadine hydrochloride?
OLOPATADINE HYDROCHLORIDE is a marketed brand name for olopatadine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olopatadine hydrochloride?
olopatadine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.